Search DIAN Tissue Requests
Catherine Marquer
SYNAPTOJANIN 1 LEVELS IN DOMINANTLY INHERITED ALZHEIMER’S DISEASE
07/05/2019
approved
DIAN-T1907
To test whether the protein levels of Synaptojanin1 are increased in dominantly inherited Alzheimer's disease (DIAD), as they are in sporadic and Down Syndrome-AD
Kaj Blennow
Truncated tau species tau224 and tau368 in CSF and P-tau181 in plasma in familial AD as indicators of pathological brain tau metabolism
08/14/2019
withdrawn
DIAN-T1908
To examine how novel CSF biomarkers for tau pathology (tau truncated at positions 224 or 368) change with onset of amyloid pathology and tau pathology, as well as clinical disease onset and progression in familial AD
To examine how plasma P-tau181 changes with onset of amyloid pathology and tau pathology, as well as clinical disease onset and progression in familial AD
N/A
Gene therapy for familial Alzheimer’s disease
09/29/2019
approved
DIAN-T1910
To determine whether introduction of wildtype PS1 can rescue γ-secretase activity in cultured fibroblasts from autosomal dominant Alzheimer disease (ADAD) patients with PSEN1 mutations
Carlos Cruchaga
Genomic-based biomarkers for Alzheimer’s Disease
10/17/2019
withdrawn
DIAN-T1912
Aim 1: To construct prediction models for AD using cell-free nucleic species.
Aim 2: To create novel prediction models using circular RNAs as biomarkers
Randall Bateman
Fluid NfL levels to be used as control and run-in data for the DIAN TU
10/18/2019
withdrawn
DIAN-T1913
To measure NfL levels in CSF and matched plasma smaples for use as control and run-in data in the DIAN TU
Oscar Harari
Brain DNA methylation in Autosomal Dominant Alzheimer’s disease
10/29/2019
approved
DIAN-T1914
Aim 1: To identify Differentially Methylated Loci (DML) in ADAD and sporadic AD and neuropath-free controls
Aim 2. To identify genetic loci modulating DML, and their downstream impact in brain transcriptomic/proteomic profiles.
Aim 3. To evaluate the causal relationship between DML and AD pathogenesis.
N/A
Therapeutic development for familial Alzheimer’s disease
09/29/2019
approved
DIAN-T1910
To determine whether therapeutic candidates can affect Abeta processing in cultured fibroblasts from autosomal dominant Alzheimer disease (ADAD) patients with PSEN1 mutations
Dennis Selkoe
Plasma Levels of an N-terminal Tau Fragment as Predictors of Cognitive Decline and Neurodegeneration in DIAN
12/10/2019
approved
DIAN-T1915
Using cross-sectional and longitudinal plasma samples from DIAN, we will assess levels of plasma NT1 (SIMOA) and correlate these with estimated years to symptom onset (EYO), rates of neurodegeneration (MRI-based), and cognitive performance (using the DIAN global cognitive composite).
Using pre-existing measures of NfL from prior DIAN studies, we will compare and contrast the associations of plasma NfL and NT1 to cognitive and neurodegenerative trajectories.
Jihwan Song
Comparison of the iPSC Characteristics between Caucasian and Asian ADAD Families
12/10/2019
DIAN-T1916
To compare charateristics of iPSCs between caucasian and asian ADAD families
Zlokovic, Berislav V. and Toga, Arthur W.
Blood-brain barrier dysfunction in autosomal dominant Alzheimer’s disease (ADAD)
02/09/2020
approved
DIAN-T2001
To evaluate the effects of ADAD mutations on the molecular biomarkers of NVU and BBB dysfunction in PSEN1 and other ADAD pre-symptomatic and symptomatic MCs compared to non-MC carriers, and determine how they relate to each other, and whether NVU/BBB dysfunction can contribute to cognitive impairment and other pathologies in ADAD.